SENORES

Senores Pharmaceuticals Ltd.

NSE: SENORES

BSE: 544319

Sector: Healthcare

Industry Group: Pharmaceuticals & Biotechnology

Industry: Pharmaceuticals

1,405.10-48.0 (-3.30%)

17 Jul, 12:00 AM

Overview

Analysis Statements Technicals Forecast Peers Resources News

Stock Scores

Quality Score

83.5 / 100

Value Score

8.7 / 100

Price Momentum Score

98.3 / 100

QVM Score

76.3 / 100

Key Metrics

Market Cap

6471.05

P/E (TTM)

56.09

P/B

6.93

P/S (TTM)

10.23

EV/EBITDA

38.50

CAPE (5Y)

128.25

ROE (TTM)

13.42

ROCE (TTM)

11.26

ROA (TTM)

8.15

Avg 3Y ROE

16.81

Earnings 3Y CAGR

118.35

Sales 3Y CAGR

161.60

Sales 5Y CAGR

Debt/Equity

0.37

Consensus TP

1111.00

Strong Buy %

50.00

Promoter Holding

45.82

Pledged %

1.90

Stock Analysis

Fundamental analysis overview of Senores Pharmaceuticals Ltd. covering key investment insights, growth drivers, risk factors, and potential red flags.

Views

Red Flags

Positive

Strong price momentum

Price Momentum score of 98.3 indicates that the stock has strong price momentum. Research has shown that stocks with higher momentum continue to outperform in the near term

What is Price Momentum score?

98.3 / 100

Analysts have been raising forward EPS estimates

Analyst EPS estimate (consensus) for forward EPS has increased by 3.99% in the last 3 months, indicating earnings momentum

What is Earnings upgrade (3M)?

Not enough data

Moderate ROE but improving trend

The company reported moderate ROE of 13.42% for 12-month ended 31 Mar 2026 but ROE improved by 160 bps from 1 year ago

What is ROE (FY)?

High and improving operating margin

The company reported strong operating margin of 21.67% for 12-month ended 31 Mar 2026 and operating margin improved by 338 bps from 1 year ago

What is Operating profit margin?

Strong revenue growth and above median growth of industry

The company delivered strong revenue growth of 58.85% for 12-month ended 31 Mar 2026 and the growth was 47.62 percentage points higher than median growth of industry

What is Sales growth (1Y)?

Median: 11.23

Value 58.85

-82.35114662

Strong EPS growth and above median growth of industry

The company delivered strong EPS growth of 63.89% for 12-month ended 31 Mar 2026 and the growth was 55.77 percentage points higher than median growth of industry

What is EPS growth (1Y)?

Low Debt to Equity, not much change from last year

The company has low Debt to Equity of 0.37 as on 31 Mar 2026 and Debt to Equity decreased marginally by 0.03 in the last 1 year

What is Debt to Equity?

Negative

Expensive and at a premium to industry median P/E

PE TTM of 56.09 indicates that the stock is expensive on a standalone basis and is at a 81.64% premium to industry median P/E

What is P/E Ratio?

Median: 30.88

Value 56.09

-44.893379.36

Low dividend yield

The company has a low dividend yield of 0.0%

What is Dividend yield?

Neutral

Company's earnings are of moderate quality

Earnings quality score of 40.0 indicates that the company's earnings are of moderate quality. Earnings quality is measured using combination of earnings persistence, probability of manipulation and earnings to cash conversion

What is Earnings quality score?

40.0 / 100

Financial Snapshot

See detailed analysis

Multi-year trends for Senores Pharmaceuticals Ltd. covering revenue, net profit, ROE, and EBITDA for a quick view of financial health over time.

Net Revenue FY

Profit After Tax FY

ROE FY

EBITDA FY

Senores Pharmaceuticals Ltd. Shareholding Pattern

Quarterly breakdown of Senores Pharmaceuticals Ltd. ownership including promoter, FII, DII, mutual fund, and public holdings as disclosed to NSE/BSE.

	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
Total Promoter	45.76	45.76	45.77	45.78	45.80	45.80	45.82
Indian Promoter	39.45	39.45	39.45	39.46	39.51	39.52	39.54
Foreign Promoter	6.32	6.32	6.32	6.32	6.28	6.28	6.28
Institutions	22.12	15.74	13.82	13.18	12.89	12.66	13.25
Mutual Funds / UTI	5.62	4.99	3.23	3.00	3.54	4.88	5.07
FI/Bank/Insurance	9.36	4.42	4.14	4.06	2.95	2.67	2.97
Govt	-	-	-	-	-	-	-
FII	5.52	4.24	4.17	3.66	4.28	3.35	3.64
Other Institutions	1.63	2.08	2.29	2.45	2.13	1.77	1.58
Non-Institution	32.11	38.48	40.40	41.04	41.31	41.54	40.93
Bodies Corporate	2.01	4.06	3.17	3.55	4.14	4.36	4.09
Others (incl. Retail) No. of shareholders	30.10 43,523	34.42 49,320	37.23 37,411	37.49 36,103	37.17 34,600	37.18 34,079	36.84 33,811

Bulk, Block and Insider Trades

Recent bulk deals, block deals, and insider trading activity in Senores Pharmaceuticals Ltd. shares as reported to NSE and BSE.

Name	Month	Transaction	Holding % pre transaction	Average price	Qty.	Transaction value
Dhruvalben Vishal Shah Other	March-2026	Market Purchase (Acquisition) 2nd Mar 2026	0.00 %	₹ 777.95	350.00	₹ 2.72 lac
RENOSEN PHARMACEUTICALS PRIVATE LIMITED Promoter Group	January-2026	Market Purchase (Acquisition) 1st Jan 2026	5.89 %	₹ 822.68	6.00 k	₹ 49.36 lac
RENOSEN PHARMACEUTICALS PRIVATE LIMITED Promoter Group	December-2025	Market Purchase (Acquisition) 18th Dec 2025	5.88 %	₹ 803.92	4.00 k	₹ 32.16 lac
Dhruvalben Vishal Shah Other	December-2025	Market Purchase (Acquisition) 16th Dec 2025	0.00 %	₹ 761.50	150.00	₹ 1.14 lac
Vinodkumar Gandalal Shah Other	December-2025	Market Purchase (Acquisition) 12th Dec 2025	0.00 %	₹ 782.96	300.00	₹ 2.35 lac
Vinodkumar Gandalal Shah Other	December-2025	Market Purchase (Acquisition) 12th Dec 2025	0.00 %	₹ 783.14	100.00	₹ 78.31 k
Pratik Sureshkumar Thakkar Designated Person	November-2025	Market Purchase (Acquisition) 18th Nov 2025	0.01 %	₹ 781.87	200.00	₹ 1.56 lac
Pratik Sureshkumar Thakkar HUF Other	September-2025	Market Purchase (Acquisition) 15th Sep 2025	0.00 %	₹ 688.26	350.00	₹ 2.41 lac
Chetan Bipinchandra Shah Director	September-2025	Market Purchase (Acquisition) 12th Sep 2025	0.01 %	₹ 713.49	500.00	₹ 3.57 lac
Ashokbhai Vijaysinh Barot Promoter & Director	August-2025	Market Purchase (Acquisition) 29th Aug 2025	7.48 %	₹ 708.18	1.00 k	₹ 7.08 lac

…

No corporate action data available.

Company Profile

Overview of Senores Pharmaceuticals Ltd. covering business description, industry classification, key management, financial ratios, and listed exchange details.

Senores Pharmaceuticals Limited is an India-based company. The Company is engaged in the development and manufacturing of a pharmaceutical product. The Company manufactures products of international quality to cater to the increasing new age demands of the global healthcare industry. The Companys pr...

Key personnel

Mr. Sanjay Shaileshbhai MajmudarD

Non-Executive Non-Independent Chairman of the Board

Mr. Deval Rajnikant ShahD

Chief Financial Officer, Whole Time Director

Mr. Chetan Bipinchandra ShahD

Chief Operating Officer, Whole Time Director

Mr. Swapnil Jatinbhai ShahD

Managing Director, Executive Director

Mr. Ashokkumar Vijaysinh BarotD

Non-Executive Non-Independent Director

Mr. Hemanshu Nitinchandra PandyaD

Non-Executive Non-Independent Director

Mr. Jitendra Babulal SanghviD

Non-Executive Non-Independent Director

Mr. Arpit Deepakkumar ShahD

Non-Executive Non-Independent Director

View all

Incorporated on

26 Dec 2017

Last Annual

31 Mar 2026

Last Interim

31 Mar 2026

No. of Employees

IPO date

30 Dec 2024

Free Float

2,09,47,621

Website

https://senorespharma.com/

Phone no.

+917929999857

Address

1101 to 1103, 11th floor, South Tower, ONE 42 opposite Jayantilal Park,, Ambali Bopal Road, AHMEDABAD, 380054, India

Frequently Asked Questions

What is the current share price of Senores Pharmaceuticals Ltd.?

The current share price of Senores Pharmaceuticals Ltd. is ₹ 1,405.10 as of 17 Jul 2026.

What is the market capitalisation of Senores Pharmaceuticals Ltd.?

The market capitalisation of Senores Pharmaceuticals Ltd. stands at ₹ 6,471.05 Cr.

What is the PE ratio of Senores Pharmaceuticals Ltd.?

The Price-to-Earnings (PE) ratio of Senores Pharmaceuticals Ltd. is 56.09 as of the latest trailing twelve months data.

What is the ROE and ROCE of Senores Pharmaceuticals Ltd.?

Senores Pharmaceuticals Ltd. has a Return on Equity (ROE) of 13.42% and a Return on Capital Employed (ROCE) of 11.26% as per the latest financial reports.

What is the 52-week high and low of Senores Pharmaceuticals Ltd.?

The 52-week high of Senores Pharmaceuticals Ltd. is - and the 52-week low is -.

What is the dividend yield of Senores Pharmaceuticals Ltd.?

The dividend yield of Senores Pharmaceuticals Ltd. is 0.00% based on the current market price.

What is the FII and DII holding in Senores Pharmaceuticals Ltd.?

Foreign Institutional Investors (FII) hold 3.64%, Domestic Institutional Investors (DII) hold 8.04% and retail/public investors hold 36.84% of Senores Pharmaceuticals Ltd. shares.

What sector does Senores Pharmaceuticals Ltd. belong to?

Senores Pharmaceuticals Ltd. operates in the Healthcare sector. 100% of analysts have a Buy or Strong Buy rating on Senores Pharmaceuticals Ltd. with a consensus target price of ₹ 1,111.00, implying 20.93% downside from current levels.

What is the beta of Senores Pharmaceuticals Ltd.?

The beta of Senores Pharmaceuticals Ltd. is 0.91, indicating its price volatility relative to the broader market. Over the past 1 year, Senores Pharmaceuticals Ltd. has delivered an absolute return of 139.78%.

What is the RSI of Senores Pharmaceuticals Ltd.?

The 14-day Relative Strength Index (RSI) of Senores Pharmaceuticals Ltd. is 61.53, placing it approaching overbought territory. An RSI above 70 is considered overbought and below 30 is considered oversold.

Senores Pharmaceuticals Ltd.

Stock Scores

Key Metrics

Share Price

Stock Analysis

Financial Snapshot

Senores Pharmaceuticals Ltd. Shareholding Pattern

Bulk, Block and Insider Trades

Company Profile

Frequently Asked Questions

Stock Analysis

Company Profile